Category: Laser/Light-based Devices
Advanced surgical lighting maker Invuity registers for an initial public offering worth $69 million.
Invuity this month filed registration papers for an initial public offering that could bring in as much as $69 million for the advanced surgical lighting maker.
San Francisco-based Invuity said it plans to list on the NASDAQ exchange under the "IVTY" symbol.
RayVio raises a $9.3 million Series B round for its UV LED technology, which it says can potentially be used in a handheld device.
RayVio emerged from stealth mode with a $9.3 million Series B round it plans to use on developing its UV LED technology.
Participants in the round included new investors Applied Ventures, Augment Ventures, New Ground Ventures and Tolero Ventures. Existing backers DCM Ventures and Capricorn Investment Group also participated.
Monteris Medical says it's drummed up a $30 million Series B round for its NeuroBlate laser robotic surgery platform.
Monteris Medical said a pair of new backers joined a $30 million Series B round it plans to use to expand the commercial footprint of its NeuroBlate robotic brain tumor laser.
Dental laser maker Biolase lands a $35 million private placement with a group of investors that includes its chairman, chief executive officer and top stockholders.
Dental laser maker Biolase (NSDQ:BIOL) said in landed a $35 million private placement with a group of investors that includes its chairman, CEO and top stockholders.
Nearly half of the patients who underwent LASIK laser eye surgery reported problems after the procedure, according to an FDA study, although only 1% said the problems interfered with their daily lives.
Some 45% of patients who had a laser eye surgery called LASIK later reported at least 1 visual symptom 3 months after the procedure, the FDA said yesterday.
Cynosure rounds out its minimally and non-invasive aesthetics portfolio with the $13.2 million acquisition of Ellman Intl. and its radiofrequency devices.
Massachusetts-based Cynosure (NSDQ:CYNO) is looking to expand its market with new radiofrequency-based devices picked up in its $13.2 million acquisition of Ellman Intl.
Ousted CEO Federico Pignatelli turns the spotlight on new leadership at his former company after resigning from the board of directors.
Former Biolase (NSDQ:BIOL) CEO Federico Pignatelli isn't ready to put down his dukes after dropping his seat on the company's board of directors.